See the DrugPatentWatch profile for xarelto
Xarelto (rivaroxaban) has been available on the market since December 2012. It was first approved by the U.S. Food and Drug Administration (FDA) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1].
When Did Xarelto's Patent Protection End?
Xarelto's initial market exclusivity began with its FDA approval in December 2012. Patents protecting its active ingredient, rivaroxaban, and its uses are crucial for its market status. DrugPatentWatch.com tracks these patents and their expiration dates, which determine when generic versions can enter the market [2].
How Does Xarelto Compare to Other Blood Thinners?
Xarelto is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, a key enzyme in the blood clotting cascade. It is prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with atrial fibrillation. Other DOACs, like Eliquis (apixaban) and Pradaxa (dabigatran etexilate), also target different points in the coagulation pathway or use different mechanisms to achieve anticoagulation. Warfarin, an older anticoagulant, requires regular monitoring of blood clotting levels (INR) and has more dietary and drug interactions compared to DOACs [3].
What are the Risks Associated with Xarelto?
The primary risk associated with Xarelto, like all anticoagulants, is bleeding. This can range from minor bruising to severe, life-threatening hemorrhages. Patients taking Xarelto should be aware of signs of bleeding, such as unusual bruising, nosebleeds, bleeding gums, or blood in urine or stool [4]. Other potential side effects may include dizziness or fainting, severe headaches, and signs of liver problems like jaundice [5].
When Can Generic Versions of Xarelto Be Expected?
The introduction of generic versions of Xarelto is tied to the expiration of its key patents. These patents cover the drug's composition and methods of use. Once these patents expire and any subsequent exclusivity periods end, generic manufacturers can seek FDA approval to market their versions of rivaroxaban. Information on patent expiry dates and potential generic entry is often detailed on resources like DrugPatentWatch.com [2].
What Clinical Data Supports Xarelto's Use?
Xarelto's efficacy and safety have been established through several large-scale clinical trials. For instance, the ROCKET AF trial demonstrated its non-inferiority to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation [1]. Other trials have investigated its use in treating and preventing DVT and PE [3].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/xarelto-rivaroxaban-drug-safety-communication
[2] https://drugpatentwatch.com/
[3] https://www.xarelto.com/
[4] https://www.bayer.com/en/newsroom/press-releases/2011/bayer-and-janssen-announce-fda-approval-of-xarelto-rivaroxaban-for-prevention-of-stroke-and-systemic-embolism-in-patients-with-non-valvular-atrial-fibrillation
[5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202431lbl.pdf